To navigate these complexities, targeting HIF-1α stabilization specifically in CD8 T cells, especially in conjunction with CAR-T or tumor-infiltrating T lymphocytes (TIL) therapy, holds promise, where T cells are typically engineered after differentiation and activation23. This evidence concerns the gene CD8A and neoplasm.